FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3094501285> ?p ?o ?g. }

• W3094501285 endingPage "3592" @default.
• W3094501285 startingPage "3582" @default.
• W3094501285 abstract "This study was to determine the cost-effectiveness of dapagliflozin in heart failure with reduced ejection fraction (HFrEF) patients in China from a perspective of health care payers.We built a Markov model to perform a cost-effectiveness analysis comparing standard treatment + dapagliflozin (10 mg, q.d.) with standard treatment for HFrEF. The base case in our simulation was a 65-year-old HFrEF patient and was modelled over 15 years. Inputs of the model were derived from the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure trial and other relevant data from China. Costs, quality-adjusted life year (QALY), and incremental cost-effectiveness ratio (ICER) were estimated for adding dapagliflozin relative to standard treatment. Costs and QALY were discounted at a 4.2% rate annually. All costs are presented in 2017 US dollars. Dapagliflozin would be considered very cost-effective if the ICER was lower than a willingness-to-pay (WTP) threshold of $8573.4. Uncertainty was assessed in our model using one-way, two-way, and probabilistic sensitivity analysis (PSA). In our base case, compared with standard treatment, adding dapagliflozin was more expensive ($5829.4 vs. $4377.1) but more effective (4.82 vs. 4.44 QALYs). The respondent ICER was $3827.6 per QALY gained at 15-year follow-up. When the simulated horizon was longer than 3.5 years, the respondent ICER became lower than the WTP threshold. The inputs with the largest impact on ICER were the cost of dapagliflozin, the cardiovascular mortality in both groups, and the cost of hospitalization for heart failure. Most results of sensitivity analysis were robust. PSA showed a similar result as the base case (ICER = $4412.5 per QALY gained). In Monte Carlo simulation, at a WTP threshold of $8573.4 per QALY, dapagliflozin was considered very cost-effective in 53.10% of the simulations.Dapagliflozin was a very cost-effective treatment option for HFrEF patients in China according to the result of our model. Our findings will help doctors and health care payers to make decisions in clinical practice. Future real-world studies of cost-effectiveness of dapagliflozin based on Chinese population were also needed." @default.
• W3094501285 created "2020-10-29" @default.
• W3094501285 creator A5023452142 @default.
• W3094501285 creator A5050046234 @default.
• W3094501285 creator A5057209439 @default.
• W3094501285 creator A5063797484 @default.
• W3094501285 creator A5070674540 @default.
• W3094501285 date "2020-10-27" @default.
• W3094501285 modified "2023-10-17" @default.
• W3094501285 title "Cost‐effectiveness of adding dapagliflozin to standard treatment for heart failure with reduced ejection fraction patients in China" @default.
• W3094501285 cites W2004351143 @default.
• W3094501285 cites W2032220099 @default.
• W3094501285 cites W2053071273 @default.
• W3094501285 cites W2113698123 @default.
• W3094501285 cites W2120312774 @default.
• W3094501285 cites W2126617656 @default.
• W3094501285 cites W2146264128 @default.
• W3094501285 cites W2315712189 @default.
• W3094501285 cites W2588656703 @default.
• W3094501285 cites W2626446274 @default.
• W3094501285 cites W2757868148 @default.
• W3094501285 cites W2778774060 @default.
• W3094501285 cites W2809099805 @default.
• W3094501285 cites W2900413769 @default.
• W3094501285 cites W2912910847 @default.
• W3094501285 cites W2939222610 @default.
• W3094501285 cites W2974260792 @default.
• W3094501285 cites W2986132895 @default.
• W3094501285 cites W2990255056 @default.
• W3094501285 cites W3012855013 @default.
• W3094501285 cites W3013689722 @default.
• W3094501285 doi "https://doi.org/10.1002/ehf2.12844" @default.
• W3094501285 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7754897" @default.
• W3094501285 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33107212" @default.
• W3094501285 hasPublicationYear "2020" @default.
• W3094501285 type Work @default.
• W3094501285 sameAs 3094501285 @default.
• W3094501285 citedByCount "25" @default.
• W3094501285 countsByYear W30945012852020 @default.
• W3094501285 countsByYear W30945012852021 @default.
• W3094501285 countsByYear W30945012852022 @default.
• W3094501285 countsByYear W30945012852023 @default.
• W3094501285 crossrefType "journal-article" @default.
• W3094501285 hasAuthorship W3094501285A5023452142 @default.
• W3094501285 hasAuthorship W3094501285A5050046234 @default.
• W3094501285 hasAuthorship W3094501285A5057209439 @default.
• W3094501285 hasAuthorship W3094501285A5063797484 @default.
• W3094501285 hasAuthorship W3094501285A5070674540 @default.
• W3094501285 hasBestOaLocation W30945012851 @default.
• W3094501285 hasConcept C112930515 @default.
• W3094501285 hasConcept C126322002 @default.
• W3094501285 hasConcept C134018914 @default.
• W3094501285 hasConcept C184834754 @default.
• W3094501285 hasConcept C2777180221 @default.
• W3094501285 hasConcept C2777422806 @default.
• W3094501285 hasConcept C2778198053 @default.
• W3094501285 hasConcept C3019080777 @default.
• W3094501285 hasConcept C555293320 @default.
• W3094501285 hasConcept C71924100 @default.
• W3094501285 hasConcept C78085059 @default.
• W3094501285 hasConceptScore W3094501285C112930515 @default.
• W3094501285 hasConceptScore W3094501285C126322002 @default.
• W3094501285 hasConceptScore W3094501285C134018914 @default.
• W3094501285 hasConceptScore W3094501285C184834754 @default.
• W3094501285 hasConceptScore W3094501285C2777180221 @default.
• W3094501285 hasConceptScore W3094501285C2777422806 @default.
• W3094501285 hasConceptScore W3094501285C2778198053 @default.
• W3094501285 hasConceptScore W3094501285C3019080777 @default.
• W3094501285 hasConceptScore W3094501285C555293320 @default.
• W3094501285 hasConceptScore W3094501285C71924100 @default.
• W3094501285 hasConceptScore W3094501285C78085059 @default.
• W3094501285 hasIssue "6" @default.
• W3094501285 hasLocation W30945012851 @default.
• W3094501285 hasLocation W30945012852 @default.
• W3094501285 hasLocation W30945012853 @default.
• W3094501285 hasOpenAccess W3094501285 @default.
• W3094501285 hasPrimaryLocation W30945012851 @default.
• W3094501285 hasRelatedWork W1971710084 @default.
• W3094501285 hasRelatedWork W2028196543 @default.
• W3094501285 hasRelatedWork W2072108749 @default.
• W3094501285 hasRelatedWork W2481234813 @default.
• W3094501285 hasRelatedWork W2891746874 @default.
• W3094501285 hasRelatedWork W3035255089 @default.
• W3094501285 hasRelatedWork W3104942557 @default.
• W3094501285 hasRelatedWork W3164268473 @default.
• W3094501285 hasRelatedWork W4207030337 @default.
• W3094501285 hasRelatedWork W4377714929 @default.
• W3094501285 hasVolume "7" @default.
• W3094501285 isParatext "false" @default.
• W3094501285 isRetracted "false" @default.
• W3094501285 magId "3094501285" @default.
• W3094501285 workType "article" @default.